Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.6952W HIGH $2.97
Volume
1.01 M
Value Traded
176.35 K
Short % Float
0.28%
+1.47%Week
+25.45%1 Month
+41.44%3 Month
+21.05%6 Month
-99.91%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
46.95 M
EPS (TTM)
-2.09
P/E Ratio
-
Ent. Value
41.25 M
Total Shares
34.01 M
Float Shares
29.97 M
Insiders
1.45%
Institutions
19.68%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
LITS Catalyst Timeline
Dated clinical, regulatory and corporate events for Lite Strategy, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lite Strategy, Inc.
259Total events
2Upcoming
60Tier-1 (high impact)
2005 to 2026Coverage
Upcoming catalysts 2
TBD
T3Preclinical PoC
Subscribe to view catalyst details
TBD
T3Preclinical PoC
Subscribe to view catalyst details
Event history 50
●R&D DayPresentation
Lite Strategy to present at 28th Annual H.C. Wainwright Global Investment Conference
●Other Regulator MilestoneEx-US Regulatory
SEC proposed Regulation Crypto Assets, open for public comment
◆Oral PresentationPresentation
Lite Strategy to attend panel at Litecoin Foundation Summit in Amsterdam
▲Other Regulator MilestoneEx-US Regulatory
SEC issued Digital Asset Interpretation identifying LTC as a digital commodity
▼Equity OfferingCorporate
MEI Pharma announces $100M private placement (PIPE) to fund Litecoin treasury strategy
●Quarterly UpdateCorporate
MEI Pharma reports Q3 fiscal year 2025 cash position and ongoing strategic alternatives evaluation
◆Pipeline PrioritizationCorporate
Evaluation of strategic alternatives ongoing, including out-licensing and M&A
▼Restructuring LayoffsCorporate
Reduction-in-force progressing in stages as strategic direction evolves
●Runway Guidance UpdateCorporate
Projected cash balance of ~$100M to fund operations through mid-2025
●Quarterly UpdateCorporate
MEI Pharma reports Q2 fiscal 2025 cash position and ongoing strategic review
▼Restructuring LayoffsCorporate
MEI Pharma commences cash preservation efforts including reduction-in-force
◆Trial InitiationvoruciclibTrial
Plan to initiate Phase 2 arm in R/R AML in 2025
Relapsed/Refractory Acute Myeloid Leukemiasource ↗
◆Enrollment CompletevoruciclibTrial
Enrollment completion for Phase 1/2 study with up to 120 patients
R/R AMLsource ↗
▼Program DiscontinuationvoruciclibCorporate
MEI Pharma discontinues clinical development of voruciclib
◆Pipeline PrioritizationCorporate
MEI Pharma continues evaluation of strategic alternatives including out-licensing and M&A
▼Program DiscontinuationvoruciclibCorporate
MEI Pharma discontinues clinical development of voruciclib
cancersource ↗
◆Pipeline PrioritizationCorporate
Board evaluates strategic alternatives including potential wind down
●Quarterly UpdateCorporate
MEI Pharma reports fiscal year end 2024 cash position of $38.3 million
▲Enrollment CompletevoruciclibTrial
Completed patient enrollment of dose expansion cohort at 300 mg dose
relapsed/refractory AMLsource ↗
▲Enrollment MilestonevoruciclibTrial
Initiation of enrollment in expansion cohort of voruciclib plus venetoclax
relapsed/refractory AMLsource ↗
▲Enrollment CompletevoruciclibTrial
Completed enrollment of group evaluating 300 mg dose of voruciclib in combination with venetoclax
relapsed or refractory acute myeloid leukemiasource ↗
▲Enrollment CompleteME-344Trial
Completed enrollment in Cohort 1 of Phase 1b study of ME-344 plus bevacizumab
relapsed colorectal cancersource ↗
◆Topline ReadoutvoruciclibClinical Data
Additional data from dose escalation portion of voruciclib in combination with venetoclax in AML expected early 2024
acute myeloid leukemia (AML)source ↗
●Poster PresentationME-344Presentation
Trials in Progress poster of ongoing Phase 1b study of ME-344 plus bevacizumab at ASCO GI 2024
refractory metastatic colorectal cancersource ↗
◆Timing GuidancevoruciclibPresentation
Key upcoming data readouts for voruciclib and ME-344 expected in first half of 2024
cancersource ↗
◆Timing GuidanceME-344Presentation
Key upcoming data readouts for voruciclib and ME-344 expected in first half of 2024
cancersource ↗
◆Type D MeetingvoruciclibFDA Meeting
Type D meeting to gain FDA's agreement on protocol amendment for Phase 2 stage at RP2D
R/R AMLsource ↗
▲Patent GrantedvoruciclibIP / Competition
Allowance of patent application in Japan for voruciclib polymorph expected
◆Enrollment CompletezandelisibTrial
COASTAL study enrollment expected to complete in 2024
relapsed/refractory follicular lymphoma or marginal zone lymphomasource ↗
●Poster PresentationvoruciclibPresentation
Poster presentation at ASH 2023 on voruciclib monotherapy and combination with venetoclax
acute myeloid leukemia (AML) or B-cell malignanciessource ↗
◆Poster PresentationvoruciclibPresentation
Poster presentation of voruciclib monotherapy dose escalation data at ASH 2023
acute myeloid leukemia or B-cell malignanciessource ↗
◆Topline ReadoutvoruciclibClinical Data
Voruciclib in combination with Venclexta expected to generate data around end of year
acute myeloid leukemiasource ↗
Past FDA Catalysts and PDUFA Decisions
How LITS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D24 / 100
Pipeline Score
$4M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.1x
rNPV / MCap
Top 86%
Micro Cap(rank 566 of 658)
Percentile Rank
Lite Strategy, Inc. faces pipeline headwinds (24/100), with $316M risk-adjusted pipeline value, led by PWT-143 in Malignancies (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PWT-143 Small moleculeCompletedNCT02521389 | Malignancies | Phase 1 | COMPLETED | 35 | Feb 24, 2017 |
Clinical Trial Results
Readouts, endpoints and source filings for every LITS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| voruciclib | acute myeloid leukemia and B-cell malignancies | Phase 1 | 2023-12-11 | favorable safety profile; no observed overlapping toxicities; meaningful anti-tumor activity; 40 patients enrolled; median age 75 years (range 63-80)Read More | inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the paRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Flynn James PDirector | Buy | 25,000 125,000 held | $0.86 | 06/24/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LITS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in LITS for Q2 2026. | ||||
LITS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LITS ranks across every disease it competes in
Competitive Position is a premium feature
See how LITS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLITS News
LITSLite Strategy Reports Fiscal Year 2026 Financial Results
Lite Strategy, Inc. reported its fiscal year 2026 financial results, marking the first year of its Litecoin treasury strategy. The company acquired over 900,000 LTC and initiated a covered call program to enhance shareholder value. Despite regulatory uncertainties, management remains optimistic about LTC's growth potential and plans to expand its treasury operations. The company also retains pharmaceutical assets for potential out-licensing.
Read more →LITSLite Strategy to Present at the 28th Annual H.C. Wainwright Global Investment Conference in New York
Lite Strategy, Inc. will present at the 28th Annual H.C. Wainwright Global Investment Conference in New York from September 14-16, 2026. The company, known for adopting Litecoin as its primary treasury reserve asset, aims to engage with institutional investors to discuss its capital markets strategy. CEO Jay File emphasized the importance of the conference for articulating their vision and building momentum.
Read more →LITSLite Strategy Repurchases 13% of Outstanding Shares Since December, Increasing Litecoin Backing Per Share
Lite Strategy, Inc. has repurchased approximately 4.9 million shares, representing 13% of its outstanding shares, since initiating its Share Repurchase Program in December 2025. The buyback was funded through treasury operations and has effectively increased the Litecoin backing per share while narrowing the discount to net asset value. The company plans to continue this program as long as it remains beneficial for stockholders.
Read more →LITS▲ +8%on this news
Lite Strategy to Attend Panel at Litecoin Foundation Summit in Amsterdam
Lite Strategy, Inc. will participate in the Litecoin Foundation Summit on June 22-23, 2026, in Amsterdam. This marks the first appearance of a NASDAQ-listed digital asset treasury company at the event, showcasing the institutional adoption of Litecoin. The panel will feature key figures from Lite Strategy and the Litecoin Foundation, discussing the future of Litecoin as a reserve asset.
Read more →LITS▼ -9.9%on this newsshared move
Lite Strategy Leads Strategic Investment in LitVM
Lite Strategy, Inc. has closed a $1.0 million strategic investment in ZK Innovations Inc., the developer of LitVM, a zero-knowledge Layer 2 platform for Litecoin. This investment aims to enhance Litecoin's functionality, enabling decentralized finance and smart contracts. Lite Strategy's CEO emphasized the importance of building infrastructure to create shareholder value. The investment aligns with the upcoming launch of LitVM's mainnet, which will introduce new capabilities to the Litecoin ecosystem.
Read more →LITS▼ -5.6%on this news
Lite Strategy Reports Fiscal 2026 Third Quarter Results
Lite Strategy, Inc. reported its fiscal 2026 third quarter results, highlighting successful treasury management and a robust covered call option program. The company generated $0.7 million in net proceeds and repurchased over 1.6 million shares. CEO Jay File emphasized the focus on generating yield from Litecoin holdings while enhancing shareholder value. The SEC's recent guidance classifying Litecoin as a digital commodity is seen as a positive development for the company and the broader Litecoin ecosystem.
Read more →LITSLite Strategy Reports Fiscal 2026 Second Quarter Results
Lite Strategy, Inc. reported its fiscal 2026 second quarter results, highlighting a strategic shift to actively manage its Litecoin (LTC) holdings. The company generated significant revenue through covered call options and initiated a $25 million stock repurchase program. Management aims to differentiate itself from passive digital asset vehicles by enhancing shareholder value and supporting the Litecoin ecosystem.
Read more →LITS▼ -5.9%on this news
Lite Strategy Reports First Quarter Fiscal Year 2026 Results; Highlights Successful Launch of $100M Litecoin Treasury Strategy and Movement into Active Capital Market Operations
Lite Strategy, Inc. (LITS) reported strong first-quarter results for fiscal year 2026, highlighting its $100 million Litecoin treasury strategy and its status as the first U.S. public company to adopt Litecoin as a primary reserve asset. The company also announced a strategic partnership with GSR to guide its digital asset treasury strategy. Despite its successes, LITS faces risks related to market fluctuations and regulatory challenges.
Read more →LITS▲ +7.8%on this news
Lite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation to Active Capital Market Operations
Lite Strategy, Inc. has announced a $25 million share repurchase program to enhance stockholder value. The program allows for shares to be bought back in the open market or through negotiated transactions. The company aims to optimize its Litecoin treasury and adapt to market conditions, although the timing and number of shares purchased will depend on market dynamics.
Read more →LITS▲ +7.8%on this news
Lite Strategy Announces $25M Share Repurchase Program, Signalling Shift From Initial Litecoin Accumulation to Active Capital Market Operations LITS Board of Directors Reaffirms Commitment to Driving Long-Term Stockholder
Lite Strategy, Inc. (LITS) announced a $25 million share repurchase program, indicating a strategic shift from accumulating Litecoin to engaging in active capital market operations. The Board of Directors aims to enhance stockholder value through this initiative, which allows for the repurchase of shares based on market conditions. The company may also implement a Rule 10b5-1 trading plan to facilitate these purchases. However, potential risks include challenges in executing the repurchase effectively and fluctuations in the value of Litecoin impacting operations.
Read more →LITSLite Strategy Celebrates 14th Anniversary of Litecoin, Taps Institutional Signals Ahead of 2026
Lite Strategy, Inc. celebrates the 14th anniversary of Litecoin, highlighting its reliability and institutional interest. The company positions itself as a pioneer in providing institutional access to Litecoin through public markets. Despite challenges like the ongoing government shutdown, Lite Strategy aims to attract investors seeking exposure to this digital asset.
Read more →LITSLite Strategy, Inc. (NASDAQ: LITS) is the first U.S.-listed public company to adopt Litecoin as its primary reserve asset. Formerly MEI Pharma, the Company has expanded its business model beyond its portfolio of drug can
Lite Strategy, Inc., formerly MEI Pharma, has rebranded to highlight its focus on adopting Litecoin as its primary reserve asset. The company has secured over $100 million in Litecoin and aims to pioneer digital asset treasury management. Alongside the rebranding, Lite Strategy continues to evaluate its drug development pipeline, suggesting a blend of innovative digital strategies with traditional biotechnology initiatives. The partnership with LTC creator Charlie Lee and GSR Ventures is expected to strengthen its market approach.
Read more →LITSMEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising SAN DIEGO, 5 August 2025 – MEI Pharma, Inc. (NASDAQ: MEIP) (“MEI” or “the
MEI Pharma, Inc. announced its acquisition of 929,548 Litecoin tokens as part of a $100 million institutional treasury strategy, making it the first U.S.-listed public company to adopt Litecoin as a reserve asset. This initiative is in partnership with GSR and guided by Litecoin founder Charlie Lee, emphasizing the scalability and reliability of Litecoin for treasury purposes. In addition to this strategic step, MEI Pharma is also planning further development in its drug candidate pipeline.
Read more →LITSMEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange Charlie Lee, the Founder of Litecoin and a lead invest
MEI Pharma recently announced a $100 million private placement aimed at initiating a Litecoin treasury strategy, making it the first publicly traded company to adopt Litecoin as a treasury reserve asset. The transaction will appoint Litecoin’s founder, Charlie Lee, to its Board of Directors and engage GSR as a digital asset advisor. This strategy reflects a significant shift toward integrating cryptocurrency into corporate financial practices, with expectations for broader adoption in traditional capital markets. The company aims to bolster its cash management framework through the holding of LTC.
Read more →LITSMEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position Evaluation of Strategic Alternatives is Ongoing SAN DIEGO--(BUSINESS WIRE) —
MEI Pharma reported its third quarter results for fiscal year 2025, indicating a cash position of $20.5 million and no debt. The company is actively evaluating strategic alternatives, including potential out-licensing and M&A opportunities, with the aim of maximizing asset value for shareholders. However, there is uncertainty surrounding the success of these strategies and a reduction in workforce is being implemented, which may affect operational capabilities.
Read more →LITSMEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position Evaluation of Strategic Alternatives is Ongoing SAN DIEGO--(BUSINESS WIRE) —
MEI Pharma reported its financial results for the second quarter of fiscal year 2025, revealing a cash position of $23.7 million. The company is actively exploring strategic alternatives, including potential mergers or out-licensing opportunities, to enhance the value of its assets. However, the evaluation process carries risks, and there is no assurance that it will result in successful transactions. Furthermore, MEI Pharma has initiated workforce reductions as part of its cash preservation efforts amid continued operational and financial challenges.
Read more →LITSMEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position Reaffirms Continuation of Evaluation of Strategic Alternatives SAN DIEGO--(BUSINESS WIRE) —
MEI Pharma reported its first-quarter results for fiscal year 2025, indicating a cash position of $26.9 million without any debt. The company confirmed its ongoing evaluation of strategic alternatives to maximize asset value, involving potential out-licensing and merger opportunities. However, they have commenced cash preservation efforts including staff reductions that will occur in stages. The press release highlighted uncertainties about the success of these strategies and warned stakeholders of various risks that may affect potential agreements.
Read more →LITSMEI Pharma Reports Fiscal Year End 2024 Cash Position Confirms Continuation of Evaluation of Strategic Alternatives SAN DIEGO--(BUSINESS WIRE) —
MEI Pharma, Inc. has reported its financial results for the fiscal year ending June 30, 2024. The company is evaluating strategic alternatives to enhance the value of its assets for shareholders, including potential mergers and acquisitions. To conserve its cash, MEI has initiated workforce reductions and stopped the clinical development of its drug voruciclib. As of the end of the fiscal year, the company holds $38.3 million in cash and equivalents, with rising concerns regarding the success of its strategic evaluations.
Read more →LITSVoruciclib: An Oral CDK9 Inhibitor for AML and Other Malignancies July 2024 Forward Looking Statements Certain information contained in this communication that are not historical in nature are forward-looking statements
The article discusses Voruciclib, an oral CDK9 inhibitor targeted at acute myeloid leukemia (AML) and other malignancies. Currently in clinical development, it is being evaluated in combination with Venetoclax, showing promise for patients who have not responded to initial therapies. The ongoing trials aim to demonstrate its safety and efficacy, with expected data readouts in late 2024 and early 2025. The article highlights both the potential benefits and inherent risks associated with the commercialization and clinical success of Voruciclib.
Read more →LITSMEI Pharma to Consider Strategic Alternatives Company Commences a Cash Preservation Plan Including a Reduction in Force SAN DIEGO--(BUSINESS WIRE)—
MEI Pharma has announced a cash preservation plan involving a workforce reduction and the cessation of its clinical development activities for voruciclib. The company's Board of Directors is exploring strategic alternatives, which may include asset sales or an orderly wind down if no viable options are identified. Leadership changes accompany this process, with key executives transitioning out, and the company intends to focus on prudent cash management during this evaluation period. Stakeholders are cautioned that the ongoing review poses significant risks to the company's future operations.
Read more →About Lite Strategy, Inc.
Headquarters9920 PACIFIC HEIGHTS BLVD, SAN DIEGO, CA, 92121
BIOPHARMAWATCH ELITE PLUS
Trade the next LITS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime